Small fiber involvement is independent from clinical pain in late-onset Pompe disease

Enax-Krumova, Elena; Dahlhaus, Iris; Görlach, Jonas; Claeys, Kristl G.; Montagnese, Federica; Schneider, llka; Sturm, Dietrich; Fangerau, Tanja; Schlierbach, Hannah; Roth, Angela; Wanschitz, Julia; Löscher, Wolfgang N.; Güttsches, Anne‐Katrin; Vielhaber, Stefan; Hasseli, Rebecca; Zunk, Lea; Krämer, Heidrun H.; Hahn, Andreas; Schöser, Benedikt; Rosenbohm, Angela; Schänzer, Anne

doi:10.1186/s13023-022-02327-4

“…The gene is found on 17q25.3 chromosome region . This rare, prevalence of 1:18,702 births, hereditary metabolic disease is predominantly manifested by muscle weakness and is therefore also classified as a myopathy [15][16][17]. The prevalence of the adult form is estimated at 1:57,000 and that of the infantile form at 1:138,000 [3][4][5][6][7][8][9][10][11][12][13][14].…”

Section: Discussionmentioning

confidence: 99%

Untitled

2023

AJBSR

0

View full text Add to dashboard Cite

Pompe disease, acid maltase disease, is a rare, autosomal recessive inherited metabolic disorder from the group of lysosomal storage diseases, which is based on a genetically caused deficiency of an enzyme and is treatable by substitution of this enzyme. Pompe disease is also known as myopathy due to acid maltase deficiency, α-1,4-glucosidase deficiency or acid α-glucosidase deficiency, glycogen storage disease type II or glycogenosis type II. It is inherited in an autosomal recessive manner. When each parent carries one copy of the mutated gene the child will be affected by Pompe disease. Pompe disease is one of the metabolic myopathies and is a glycogen storage disease. The incidence of Pompe disease is estimated to be approximately 1:40,000-1:200000. The disease is due to a genetic deficiency or complete absence of the lysosomal Enzyme Acid α-glucosidase. GAA degrades glycogen to glucose, particularly in the lysosomes of muscle tissue. Due to the lack of enzyme, glycogen derived from autophagy accumulates in the lysosomes. As with other lysosomal storage diseases, the cells are affected in their function first, and increasingly as the disease progresses, the entire muscle tissue is affected. Once damage has occurred, it is usually irreversible. Three different types are known, an infantile form (IOPD), a non-classic IOPD without cardiac involvement and a late onset LOPD. IOPD patients show a GAA enzymatic activity of 1-3 %, in LOPD patients an enzyme activity of 2-40 % of GAA is present. Diagnosis will be confirmed by GAA enzyme analysis prenatally in amniotic fluid and postnatally by alpha 1-4 glucosidase activity in the blood. The later the disease appears the better it can be treated. This manuscript focuses on the present therapeutical options to treat Pompe disease in children and shed light on present molecular research curing the disease.

show abstract

“…The gene is found on 17q25.3 chromosome region . This rare, prevalence of 1:18,702 births, hereditary metabolic disease is predominantly manifested by muscle weakness and is therefore also classified as a myopathy [15][16][17]. The prevalence of the adult form is estimated at 1:57,000 and that of the infantile form at 1:138,000 [3][4][5][6][7][8][9][10][11][12][13][14].…”

Section: Discussionmentioning

confidence: 99%

What is the Clue to Cure Pompe Disease in Childhood?

Bittmann

2023

AJBSR

0

View full text Add to dashboard Cite

Pompe disease, acid maltase disease, is a rare, autosomal recessive inherited metabolic disorder from the group of lysosomal storage diseases, which is based on a genetically caused deficiency of an enzyme and is treatable by substitution of this enzyme. Pompe disease is also known as myopathy due to acid maltase deficiency, α-1,4-glucosidase deficiency or acid α-glucosidase deficiency, glycogen storage disease type II or glycogenosis type II. It is inherited in an autosomal recessive manner. When each parent carries one copy of the mutated gene the child will be affected by Pompe disease. Pompe disease is one of the metabolic myopathies and is a glycogen storage disease. The incidence of Pompe disease is estimated to be approximately 1:40,000-1:200000. The disease is due to a genetic deficiency or complete absence of the lysosomal Enzyme Acid α-glucosidase. GAA degrades glycogen to glucose, particularly in the lysosomes of muscle tissue. Due to the lack of enzyme, glycogen derived from autophagy accumulates in the lysosomes. As with other lysosomal storage diseases, the cells are affected in their function first, and increasingly as the disease progresses, the entire muscle tissue is affected. Once damage has occurred, it is usually irreversible. Three different types are known, an infantile form (IOPD), a non-classic IOPD without cardiac involvement and a late onset LOPD. IOPD patients show a GAA enzymatic activity of 1-3 %, in LOPD patients an enzyme activity of 2-40 % of GAA is present. Diagnosis will be confirmed by GAA enzyme analysis prenatally in amniotic fluid and postnatally by alpha 1-4 glucosidase activity in the blood. The later the disease appears the better it can be treated. This manuscript focuses on the present therapeutical options to treat Pompe disease in children and shed light on present molecular research curing the disease.

show abstract